Nefropatía Inducida por Contraste

Mecanismos de daño renal y factores de riesgo

• La administración de medios de contraste puede manifestarse como una alteración en los parámetros de laboratorio de la función renal, aunque con menor frecuencia requiere tratamiento con diálisis o resulta en daño permanente, según el Journal of the American College of Cardiology 1
• Insuficiencia renal preexistente (especialmente con función renal alterada) es un factor de riesgo para desarrollar nefropatía inducida por contraste, según la European Journal of Nuclear Medicine and Molecular Imaging 2, 3
• Diabetes mellitus, particularmente cuando coexiste con insuficiencia renal, es un factor de riesgo para desarrollar nefropatía inducida por contraste, según el Journal of the American College of Cardiology 1
• Deshidratación o depleción de volumen es un factor de riesgo para desarrollar nefropatía inducida por contraste, según el American Journal of Kidney Diseases 4
• Uso concomitante de medicamentos nefrotóxicos es un factor de riesgo para desarrollar nefropatía inducida por contraste, según la European Journal of Nuclear Medicine and Molecular Imaging 3
• Dosis alta de medio de contraste es un factor de riesgo para desarrollar nefropatía inducida por contraste, según la European Journal of Nuclear Medicine and Molecular Imaging 3
• Edad mayor de 70 años es un factor de riesgo para desarrollar nefropatía inducida por contraste, según la European Journal of Nuclear Medicine and Molecular Imaging 3
• Enfermedad cardiovascular es un factor de riesgo para desarrollar nefropatía inducida por contraste, según la European Journal of Nuclear Medicine and Molecular Imaging 3

Estrategias de prevención

• Verificar la función renal antes de la administración de contraste en todos los pacientes considerados en riesgo de nefrotoxicidad, según la European Journal of Nuclear Medicine and Molecular Imaging 2, 3
• La tasa de filtración glomerular estimada es un mejor predictor de disfunción renal que el nivel de creatinina solo, según la European Journal of Nuclear Medicine and Molecular Imaging 2
• Suspender medicamentos nefrotóxicos (como antiinflamatorios no esteroideos y aminoglucósidos) al menos 24 horas antes del procedimiento, según el American Journal of Kidney Diseases 4

Manejo de medicamentos específicos

• En pacientes que toman metformina y van a recibir contraste intravenoso, se debe suspender la metformina en el momento del procedimiento y mantenerla suspendida durante 48 horas después, según la European Journal of Nuclear Medicine and Molecular Imaging 2, 3
• Si el riesgo de nefrotoxicidad es alto, la metformina solo debe reiniciarse después de reevaluar la función renal y confirmar que es normal, según la European Journal of Nuclear Medicine and Molecular Imaging 2, 3

Consideraciones adicionales

• Aunque algunos estudios en animales sugieren que los agentes de baja osmolaridad pueden exhibir menor toxicidad renal, algunos ensayos clínicos prospectivos no han demostrado una reducción en el riesgo de nefropatía inducida por contraste cuando se emplean los nuevos agentes no iónicos durante la cateterización cardíaca, según el Journal of the American College of Cardiology 1
• Los compuestos basados en gadolinio utilizados como agentes de contraste para resonancia magnética están asociados con una incidencia mucho menor de nefrotoxicidad y reacciones alérgicas que los materiales de contraste yodados utilizados para angiografía por tomografía computarizada y angiografía convencional, según Stroke y Circulation 5, 6

Metformin Use in Patients Undergoing Contrast Agent Examinations

Introduction to Lactic Acidosis Risk Factors

• The European Society of Nuclear Medicine recommends that metformin be discontinued 48 hours before and after contrast agent examinations to reduce the risk of lactic acidosis, as contrast agents can cause acute kidney injury, leading to metformin accumulation and increased risk of lactic acidosis 7
• Lactic acidosis is a rare but serious complication with a high mortality rate of 30-50%, occurring in 2-9 per 100,000 patients per year 8

Risk Factors for Contrast-Induced Nephropathy

• The European Journal of Nuclear Medicine and Molecular Imaging suggests that pre-existing kidney dysfunction (eGFR < 60 mL/min/1.73 m²) is a risk factor for contrast-induced nephropathy 7
• The use of high-dose contrast agents, as well as the presence of heart disease, are also risk factors for contrast-induced nephropathy 7

Recommendations for Metformin Discontinuation

• The European Journal of Nuclear Medicine and Molecular Imaging and Anaesthesia recommend that metformin be discontinued at the time of contrast agent examination and not resumed for 48 hours after the examination 7, 8
• In cases of high risk of nephrotoxicity, metformin should only be resumed after kidney function has been re-evaluated and found to be normal 7

Considerations for Patient Care

• The American College of Cardiology is not mentioned in this article, however, the European Journal of Nuclear Medicine and Molecular Imaging suggests that alternative blood glucose control medications should be considered during contrast agent examinations 7
• The strength of evidence for these recommendations is limited, but a conservative approach is currently recommended to prioritize patient safety 7, 8

Contrast-Induced Nephropathy Prevention

Risk Factors for Contrast-Induced Nephropathy

• The American Journal of Kidney Diseases recommends that patients with pre-existing kidney disease are at higher risk for contrast-induced nephropathy, particularly those with diabetes and kidney disease 9, 10
• Patients with diabetes and kidney disease have a significantly increased risk of contrast-induced nephropathy, with a risk of 20-50% 10

Prevention Strategies for Contrast-Induced Nephropathy

• The American Journal of Kidney Diseases and the Journal of the American College of Cardiology recommend that all patients should have their kidney function evaluated before contrast agent administration, and that adequate hydration before and after the procedure is a basic strategy for preventing contrast-induced nephropathy 9, 11, 12
• The American Journal of Kidney Diseases and the European Heart Journal recommend that the use of contrast agents should be minimized as much as possible, and that low-osmolar or iso-osmolar contrast agents should be used in high-risk patients 9, 12
• The American Journal of Kidney Diseases recommends that patients with eGFR < 60 mL/min/1.73m² are at high risk for contrast-induced nephropathy and require special attention 9

Follow-Up After Contrast Agent Administration

• The American Journal of Kidney Diseases recommends that kidney function should be re-evaluated within 48-96 hours after contrast agent administration 9

Alternative Options

• The American Journal of Kidney Diseases recommends that alternative imaging methods, such as non-contrast imaging or ultrasound contrast agents, should be considered for patients with severe kidney disease, if possible 9

Metformin Management in Patients with Impaired Renal Function Undergoing Contrast CT Scan

Risk Assessment and Management

• Withhold metformin for 48 hours after the procedure in patients with impaired renal function (eGFR 30-60 mL/min/1.73 m²), and re-evaluate eGFR at 48 hours post-procedure before restarting metformin, as recommended by the European Journal of Nuclear Medicine and Molecular Imaging 13, 14
• Never assume renal function is adequate—always verify eGFR before contrast administration, according to the European Journal of Nuclear Medicine and Molecular Imaging 13, 14

Alternative Glucose Management

• Consider alternative glucose-controlling medications during the 48-hour metformin hold period in patients with impaired renal function (eGFR 30-60 mL/min/1.73 m²), as suggested by the European Journal of Nuclear Medicine and Molecular Imaging 13, 14

Metformin Management Before CT Scan with Contrast

Risk-Stratified Approach Based on Renal Function

• The European Journal of Nuclear Medicine and Molecular Imaging recommends stopping metformin at the time of contrast administration for patients with normal renal function, and holding for 48 hours post-procedure, then restarting if renal function remains stable 15
• For patients with normal renal function, the evidence shows that stopping metformin at the time of contrast administration and holding for 48 hours post-procedure is sufficient, as the risk of lactic acidosis is negligible, according to the European Journal of Nuclear Medicine and Molecular Imaging 15

Management of Metformin in Elderly Diabetic Patients with Renal Impairment

Immediate Metformin Management

• The American Geriatrics Society recommends that metformin be discontinued immediately and held for at least 48 hours after CT contrast administration in patients with a GFR of 54 mL/min, due to the high risk of lactic acidosis, with a mortality rate of 30-50% 16, 17, 18
• Elderly patients (>65 years) have a substantially elevated risk of lactic acidosis, with 20% mortality in documented cases, and metformin should be withheld at the time of contrast administration and not restarted for 48 hours 17, 18
• The American Geriatrics Society suggests that a baseline GFR of 54 mL/min is already at the threshold where metformin carries increased risk, and renal function reassessment is necessary before metformin resumption 19

Hyperglycemia Management During Metformin Hold

• The American Diabetes Association recommends considering basal insulin as a safe option for glucose control during the acute period of metformin hold, starting at 10 units daily or 0.1-0.2 units/kg/day, titrating by 2 units every 3 days to achieve fasting glucose <130 mg/dL, although the specific citation for this is not provided, an alternative source suggests avoiding SGLT2 inhibitors in this acute setting given renal impairment and contrast exposure 20

Critical Pitfalls to Avoid

• The American College of Clinical Pharmacology advises against restarting metformin prematurely in patients with a combination of GFR <60 mL/min, recent contrast, elderly age, and acute illness, due to the high mortality risk if lactic acidosis develops 17, 18
• The Journal of the American Geriatrics Society recommends avoiding chlorpropamide in elderly patients due to prolonged half-life and severe hypoglycemia risk 19
• The American Society of Nephrology suggests monitoring for contrast-induced nephropathy in patients with multiple risk factors, including age >70, diabetes, and baseline GFR 54 mL/min, as worsening renal function would contraindicate metformin resumption 19

Medications to Hold Prior to Contrast CT Scan

Introduction to Contrast-Induced Nephropathy Prevention

• The American Journal of Kidney Diseases recommends stopping nephrotoxic medications (NSAIDs, aminoglycosides, amphotericin B) 24-48 hours before the procedure when possible, as they increase the risk of contrast-induced nephropathy, particularly in patients with pre-existing chronic kidney disease and diabetes 21
• The American College of Cardiology recommends not routinely discontinuing beta-blockers and nitroglycerin for standard contrast CT, as they are actually recommended for cardiac CT to optimize image quality (heart rate <60 bpm, coronary vasodilation) 22

Patient Preparation and Medication Management

• The European Journal of Nuclear Medicine and Molecular Imaging suggests that patients with renal impairment should always have their eGFR verified before contrast administration, and consider alternative non-contrast imaging in patients with eGFR <30 mL/min/1.73 m² 23
• The American Journal of Kidney Diseases recommends adequate hydration with 0.9% normal saline or sodium bicarbonate at 1 mL/kg/h for 6-12 hours before procedure, and prehydration with 1 liter of water 2 hours prior to contrast reduces nephrotoxicity risk 21
• The European Journal of Nuclear Medicine and Molecular Imaging suggests premedication with corticosteroids and antihistamines for patients with previous anaphylactoid reactions 23

Special Considerations for High-Risk Patients

• The American Journal of Kidney Diseases recommends minimizing contrast volume, especially in patients with baseline renal impairment, and considering iso-osmolar or nonionic contrast in high-risk patients 21
• The American Journal of Kidney Diseases suggests considering hemofiltration in patients with serum creatinine >2 mg/dL 21
• The European Journal of Nuclear Medicine and Molecular Imaging recommends watching for volume overload in patients with CKD stage 4 or congestive heart failure 23

Management of Medications and Risk Assessment for Iodinated Contrast‑Enhanced CT

Medication Management Around Contrast Administration

• Metformin should be stopped at the time of the CT scan and withheld for 48 hours after the procedure in patients with an estimated glomerular filtration rate (eGFR) of 30–60 mL/min/1.73 m² – to reduce the risk of lactic acidosis when contrast‑induced nephropathy occurs. [24][25]26
• If the patient has a high risk of nephrotoxicity, metformin may be restarted only after renal function has been re‑evaluated and confirmed to be normal. 25
• Beta‑blockers and calcium‑channel blockers (including verapamil) are recommended, not discontinued, for cardiac CT examinations to achieve optimal heart‑rate control and improve image quality. 27

High‑Risk Factors for Contrast‑Induced Nephropathy (CIN)

• Pre‑existing renal insufficiency (eGFR < 60 mL/min/1.73 m²) markedly increases the risk of CIN. 25
• Diabetes mellitus, particularly when accompanied by renal disease, is a recognized CIN risk factor. 25
• Concurrent use of nephrotoxic drugs (e.g., NSAIDs, aminoglycosides, amphotericin B) elevates CIN risk. 25
• Higher volumes of iodinated contrast agent are associated with greater CIN incidence. 25
• Advanced age (> 70 years) contributes to increased susceptibility to CIN. 25
• Underlying cardiovascular disease is an additional predictor of CIN. 25

Essential Pre‑Contrast Evaluation

• Measure eGFR in all patients with risk factors (age > 60 years, diabetes, hypertension, known renal disease) before administering iodinated contrast. This ensures appropriate risk stratification. 25
• eGFR is a more reliable predictor of post‑contrast renal dysfunction than serum creatinine alone. 25

Common Pitfall Regarding Metformin and Verapamil

• Metformin must be held in diabetic patients with impaired renal function (eGFR 30–60 mL/min/1.73 m²) around contrast exposure, whereas verapamil does not require discontinuation and should be continued to avoid uncontrolled hypertension or tachycardia. [24][26]